Background Chronic inflammation and elevated reactive oxygen species are key contributors to hepatocellular carcinoma (HCC) ...

In patients with small intestinal Crohn’s disease (CD), there is a need for a simple, non-invasive test to reduce dependence on invasive procedures (eg, enteroscopy) and costly imaging (eg, MRI or CT ...

A high adenoma detection rate (ADR) is vital for effective colorectal cancer (CRC) screening, but evidence suggests limited additional benefit beyond a certain threshold. In a pooled analysis of five ...

Background Liver metastasis is a major cause of mortality in patients with colorectal cancer (CRC). Understanding how CRC cells influence the formation of hepatic premetastatic niches (PMNs) is ...

Iron deficiency anaemia (IDA) is a major cause of morbidity and burden of disease worldwide. It can generally be diagnosed by blood testing and remedied by iron replacement therapy (IRT) using the ...

Transcription factors of the family p53 have emerged as an important set of tumour suppressors, able to regulate various cell functions like cell cycle arrest, differentiation, DNA repair, apoptosis ...

Introduction Neurodiversity (ND) encompasses diagnoses of attention deficit hyperactivity disorder (ADHD), autism spectrum disorders (ASD), dyslexia and dyspraxia. Studies describe overlap of clinical ...

Methods Short-term external funding was secured for a pilot to assess patients from primary care with suspected NAFLD and indeterminate Fib4 test in a dedicated Band 7 specialist nurse-led clinic, ...

Introduction Iron deficiency anaemia (IDA) is common with BSG guidance suggesting Gastrointestinal (GI) blood loss from colonic or gastric cancer, and malabsorption in coeliac disease are the most ...

Knowledge on SARS-CoV-2 infection and its resultant COVID-19 in liver diseases has rapidly increased during the pandemic. Hereby, we review COVID-19 liver manifestations and pathophysiological aspects ...

Background and aims: This study evaluates the long-term safety of infliximab in patients with inflammatory bowel disease (IBD) treated with the drug over a 14-year period. Methods: The medical records ...

Objective We evaluated the histamine 1 receptor antagonist ebastine as a potential treatment for patients with non-constipated irritable bowel syndrome (IBS) in a randomised, placebo-controlled phase ...